AFT Pharmaceutical awarded R&D grant by Callaghan Innovation

AFT Pharmaceuticals has today been announced as a recipient of a government Technology Development Grant (TDG) by Callaghan Innovation.

The TDG grants are valued at 20% of the R&D spend of each business (up to a maximum of $2.4 million per year for three years). AFT Pharmaceuticals has been awarded a total of $3.85M to assist with R&D expenditure.

Dr Hartley Atkinson, Managing Director at AFT Pharmaceuticals, welcomed today’s announcement by Hon Steven Joyce, Minister of Science and Innovation.

“We are hugely appreciative of the government’s support. New and improved product development sits at the heart of this company,” said Dr Atkinson. “It drives us day-to-day and it’s allowed us to compete on the world stage in a very competitive industry. But R&D in the pharmaceutical space is very expensive, so we appreciate the government assisting with some of these costs. This money will help with a variety of trial work and will help us move faster in getting products to overseas markets.”

Read the Minister’s media release here.

November 20, 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…

Read More

November 12, 2025

AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market 

AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…

Read More

September 25, 2025

On track for $300m FY27 revenue; positive iron IV study result

– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …

Read More